Background: For the last decade, compelling evidence on hydroxyurea (HU) efficacy in certain adult patients with sickle cell disease (SCD) has supported recommendations for use of this drug to decrease morbidity and medical costs. Despite these benefits, HU therapy is underused in patients meeting treatment criteria. The purpose of this study was to develop and evaluate an educational video to empower patients and their families to initiate a conversation with their physicians on the benefits and risks of HU, encouraging a shared decision-making process.
Methods: Patients with SCD and physicians with prominence in the sickle cell community were selected to participate in the video based on their communication skills. They were encouraged to answer interview questions on camera with language that could be easily understood by all patients. Two focus groups participated in the development process verifying the messages in the video were clear and easy to understand. A pre- and postdesign survey of patients was performed to assess patient acceptability and utility of the video.
Results: A 15-minute educational video was produced and modified from input of the focus groups. Impact of the refined educational video was evaluated with a patient survey. Patients expressed a strong desire after viewing the video to learn about potential benefits of HU. Furthermore, the video was useful in heightening the intent of patients to ask their health care providers about HU therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0027-9684(15)30853-1 | DOI Listing |
Clin Cancer Res
January 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Purpose: Renal medullary carcinoma (RMC) is a highly aggressive malignancy defined by the loss of the SMARCB1 tumor suppressor. It mainly affects young individuals of African descent with sickle cell trait, and it is resistant to conventional therapies used for other renal cell carcinomas. This study aimed to identify potential biomarkers for early detection and disease monitoring of RMC.
View Article and Find Full Text PDFPediatr Pulmonol
January 2025
Department of Internal Medicine, Division of Pulmonology, Kenyatta National Hospital, Nairobi, Kenya.
Indian J Clin Biochem
January 2025
ICMR-National Institute of Research in Tribal Health, Jabalpur, 482003 India.
Sickle cell disease (SCD) and thalassemia are the most common hereditary disorders encountered in Central India. Timely identification of these disorders is critical to reduction in severe clinical manifestations and for identifying disease burden. Present study reports spectrum of hemoglobinopathies among the referred anemia patients to single centre in central India.
View Article and Find Full Text PDFIndian J Clin Biochem
January 2025
Department of Pathology, All India Institute of Medical Sciences, Raipur, Chhattisgarh India.
Unlabelled: The heterogeneity in clinical presentations in sickle cell disease (SCD) alters between crisis and steady state phases. Considering the pathophysiology, it is crucial to establish a disease-specific reference interval for hematological and biochemical parameters and identify the sensitive predictive markers for crisis. The case-control study included fifty-four healthy control, forty SCD cases in crisis state, and forty-six steady state cases.
View Article and Find Full Text PDFInt J Public Health
January 2025
Division of Hematology, Cincinnati Children's Hospital Medical Center Global Health Center, Cincinnati Children's Hospital Medical Center Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!